Cargando…
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic sta...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848944/ https://www.ncbi.nlm.nih.gov/pubmed/31768269 http://dx.doi.org/10.15420/cfr.2019.11.2 |
_version_ | 1783469108148305920 |
---|---|
author | Bistola, Vasiliki Arfaras-Melainis, Angelos Polyzogopoulou, Eftihia Ikonomidis, Ignatios Parissis, John |
author_facet | Bistola, Vasiliki Arfaras-Melainis, Angelos Polyzogopoulou, Eftihia Ikonomidis, Ignatios Parissis, John |
author_sort | Bistola, Vasiliki |
collection | PubMed |
description | Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit. |
format | Online Article Text |
id | pubmed-6848944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Radcliffe Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-68489442019-11-25 Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice Bistola, Vasiliki Arfaras-Melainis, Angelos Polyzogopoulou, Eftihia Ikonomidis, Ignatios Parissis, John Card Fail Rev Clinical Practice Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit. Radcliffe Cardiology 2019-11-04 /pmc/articles/PMC6848944/ /pubmed/31768269 http://dx.doi.org/10.15420/cfr.2019.11.2 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. |
spellingShingle | Clinical Practice Bistola, Vasiliki Arfaras-Melainis, Angelos Polyzogopoulou, Eftihia Ikonomidis, Ignatios Parissis, John Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title | Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_full | Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_fullStr | Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_full_unstemmed | Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_short | Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_sort | inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice |
topic | Clinical Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848944/ https://www.ncbi.nlm.nih.gov/pubmed/31768269 http://dx.doi.org/10.15420/cfr.2019.11.2 |
work_keys_str_mv | AT bistolavasiliki inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT arfarasmelainisangelos inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT polyzogopouloueftihia inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT ikonomidisignatios inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT parissisjohn inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice |